• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Validation and reproducibility assessment of tigecycline MIC determinations by Etest.用Etest法测定替加环素最低抑菌浓度的验证与重复性评估
J Clin Microbiol. 2007 Aug;45(8):2474-9. doi: 10.1128/JCM.00089-07. Epub 2007 May 23.
2
Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method.采用英国抗菌化疗学会(BSAC)方法测定替加环素药敏试验的纸片折点并评估E试验法。
J Antimicrob Chemother. 2007 Oct;60(4):770-4. doi: 10.1093/jac/dkm297. Epub 2007 Aug 18.
3
Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.针对26474株血流感染分离株进行的替加环素活性检测:来自六大洲的菌株集合。
Diagn Microbiol Infect Dis. 2005 Jul;52(3):181-6. doi: 10.1016/j.diagmicrobio.2005.05.005.
4
Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery.住院患者术后发生继发性腹膜炎时采集样本的分离株对替加环素的敏感性。
Diagn Microbiol Infect Dis. 2010 Mar;66(3):308-13. doi: 10.1016/j.diagmicrobio.2009.10.018.
5
In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007.替加环素和对照药物对革兰氏阴性和革兰氏阳性菌的全球分离株的体外活性:替加环素评价和监测试验 2004-2007 年。
Diagn Microbiol Infect Dis. 2009 Nov;65(3):288-99. doi: 10.1016/j.diagmicrobio.2009.07.010. Epub 2009 Sep 4.
6
Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.替加环素对意大利收集的革兰氏阴性和革兰氏阳性病原体的体外活性。
Chemotherapy. 2008;54(1):43-9. doi: 10.1159/000112415. Epub 2007 Dec 10.
7
Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of Gram-positive cocci.台湾地区针对替加环素对革兰氏阳性球菌临床分离株体外活性的全国性监测。
Int J Antimicrob Agents. 2008 Nov;32 Suppl 3:S184-7. doi: 10.1016/S0924-8579(08)70025-6.
8
Epidemiological MIC cut-off values for tigecycline calculated from Etest MIC values using normalized resistance interpretation.使用标准化耐药性解释从Etest MIC值计算得出的替加环素的流行病学MIC临界值。
J Antimicrob Chemother. 2006 Mar;57(3):498-505. doi: 10.1093/jac/dki489. Epub 2006 Jan 12.
9
Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp.检测方法对替加环素针对推测为替加环素不敏感的不动杆菌属细菌活性谱的影响
J Antimicrob Chemother. 2009 Jul;64(1):69-72. doi: 10.1093/jac/dkp169. Epub 2009 May 17.
10
Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study.替加环素对西班牙医疗中心临床分离株的抗菌活性。第二项多中心研究。
Diagn Microbiol Infect Dis. 2006 Dec;56(4):437-44. doi: 10.1016/j.diagmicrobio.2006.07.005. Epub 2006 Sep 1.

引用本文的文献

1
Secondary bacterial infections of Carbapenem-Resistant Acinetobacter baumannii in patients with COVID-19 admitted to Chinese ICUs.中国重症监护病房收治的新冠肺炎患者中耐碳青霉烯类鲍曼不动杆菌的继发性细菌感染
BMC Microbiol. 2025 May 22;25(1):319. doi: 10.1186/s12866-025-04032-1.
2
Antimicrobial Susceptibility Testing for Enterococci.肠球菌的抗菌药物敏感性测试。
J Clin Microbiol. 2022 Sep 21;60(9):e0084321. doi: 10.1128/jcm.00843-21. Epub 2022 Jun 13.
3
Phages for Phage Therapy: Isolation, Characterization, and Host Range Breadth.用于噬菌体疗法的噬菌体:分离、表征及宿主范围广度
Pharmaceuticals (Basel). 2019 Mar 11;12(1):35. doi: 10.3390/ph12010035.
4
Comparison of Etest, disk diffusion, and broth macrodilution for in vitro susceptibility testing of Rhodococcus equi.用于马红球菌体外药敏试验的Etest、纸片扩散法和肉汤稀释法的比较。
J Clin Microbiol. 2015 Jan;53(1):314-8. doi: 10.1128/JCM.02673-14. Epub 2014 Nov 5.
5
Clinical and microbiological characteristics of tigecycline non-susceptible Klebsiella pneumoniae bacteremia in Taiwan.台湾地区替加环素不敏感肺炎克雷伯菌菌血症的临床和微生物学特征。
BMC Infect Dis. 2014 Jan 1;14:1. doi: 10.1186/1471-2334-14-1.
6
Comparative evaluation of tigecycline susceptibility testing methods for expanded-spectrum cephalosporin- and carbapenem-resistant gram-negative pathogens.比较替加环素对超广谱头孢菌素和碳青霉烯类耐药革兰氏阴性病原体敏感性检测方法。
J Clin Microbiol. 2012 Nov;50(11):3747-50. doi: 10.1128/JCM.02037-12. Epub 2012 Aug 29.
7
In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli.多药耐药肺炎克雷伯菌和大肠埃希菌体内出现替加环素耐药。
Antimicrob Agents Chemother. 2012 Aug;56(8):4516-8. doi: 10.1128/AAC.00234-12. Epub 2012 May 29.
8
First comprehensive evaluation of the M.I.C. evaluator device compared to Etest and CLSI reference dilution methods for antimicrobial susceptibility testing of clinical strains of anaerobes and other fastidious bacterial species.首次全面评估 M.I.C. 评估器设备与 Etest 和 CLSI 参考稀释方法在厌氧菌和其他苛养细菌临床分离株的抗菌药物敏感性测试中的比较。
J Clin Microbiol. 2012 Apr;50(4):1153-7. doi: 10.1128/JCM.05397-11. Epub 2012 Jan 11.
9
Influence of media and testing methodology on susceptibility to tigecycline of Enterobacteriaceae with reported high tigecycline MIC.报告中高替加环素 MIC 的肠杆菌科对替加环素的敏感性受培养基和检测方法的影响。
J Clin Microbiol. 2010 Jun;48(6):2243-6. doi: 10.1128/JCM.00119-10. Epub 2010 Mar 29.
10
In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from a Belgian hospital.替加环素对比利时一家医院分离出的耐多药肠杆菌科细菌的体外活性。
Eur J Clin Microbiol Infect Dis. 2009 Apr;28(4):381-4. doi: 10.1007/s10096-008-0629-9. Epub 2008 Sep 19.

本文引用的文献

1
Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections.对替加环素用于治疗复杂性皮肤及皮肤结构感染的3期临床试验中分离出的金黄色葡萄球菌菌株进行甲氧西林和四环素耐药基因出现情况的诊断性聚合酶链反应分析。
Antimicrob Agents Chemother. 2006 Feb;50(2):505-10. doi: 10.1128/AAC.50.2.505-510.2006.
2
Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic.替加环素:对首个甘氨酰环素类抗生素的临床前和临床研究综述
Drugs Today (Barc). 2005 Oct;41(10):637-59. doi: 10.1358/dot.2005.41.10.937460.
3
Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates.培养基年龄及添加生物催化性氧还原试剂氧化酶对替加环素针对近期临床分离株的体外活性的影响。
Antimicrob Agents Chemother. 2005 Sep;49(9):3910-8. doi: 10.1128/AAC.49.9.3910-3918.2005.
4
Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method.采用肉汤稀释法进行替加环素的最低抑菌浓度(MIC)检测时,需要使用新鲜培养基或添加生物催化性氧还原试剂Oxyrase,以规范检测方法。
Antimicrob Agents Chemother. 2005 Sep;49(9):3903-9. doi: 10.1128/AAC.49.9.3903-3909.2005.
5
In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).替加环素对全球替加环素评估与监测试验(TEST项目,2004年)中6792株革兰氏阴性和革兰氏阳性临床分离菌株的体外活性。
Diagn Microbiol Infect Dis. 2005 Jul;52(3):215-27. doi: 10.1016/j.diagmicrobio.2005.06.001.
6
The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.替加环素治疗复杂性腹腔内感染的疗效和安全性:汇总临床试验数据分析
Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S354-67. doi: 10.1086/431676.
7
The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.替加环素治疗皮肤及皮肤结构感染的疗效与安全性:两项与万古霉素-氨曲南对比的双盲3期研究结果
Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S341-53. doi: 10.1086/431675.
8
In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.替加环素对参与复杂性皮肤和皮肤结构感染及复杂性腹腔内感染治疗的3期临床试验患者分离株的体外活性。
Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S315-32. doi: 10.1086/431673.
9
Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936).外排转运蛋白基因对大肠杆菌对替加环素(GAR-936)敏感性的影响。
Antimicrob Agents Chemother. 2004 Jun;48(6):2179-84. doi: 10.1128/AAC.48.6.2179-2184.2004.
10
Tetracycline therapy: update.四环素疗法:最新进展。
Clin Infect Dis. 2003 Feb 15;36(4):462-7. doi: 10.1086/367622. Epub 2003 Jan 28.

用Etest法测定替加环素最低抑菌浓度的验证与重复性评估

Validation and reproducibility assessment of tigecycline MIC determinations by Etest.

作者信息

Bolmström Anne, Karlsson Asa, Engelhardt Anette, Ho Phion, Petersen Peter J, Bradford Patricia A, Jones C Hal

机构信息

AB BIODISK, Solna, Sweden.

出版信息

J Clin Microbiol. 2007 Aug;45(8):2474-9. doi: 10.1128/JCM.00089-07. Epub 2007 May 23.

DOI:10.1128/JCM.00089-07
PMID:17522277
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1951261/
Abstract

A multicenter study was conducted to validate Etest tigecycline compared to the Clinical Laboratory Standards Institute reference broth microdilution and agar dilution methodologies. A large collection of gram-negative (n = 266) and gram-positive (n = 162) aerobic bacteria, a collection of anaerobes (n = 385), and selected collections of nonpneumococcal streptococci (n = 369), Streptococcus pneumoniae (n = 372), and Haemophilus influenzae (n = 372) were tested. Strains with reduced susceptibility to tigecycline were used with all test methods. The Etest showed excellent inter- and intralaboratory reproducibility for all organism groups tested regardless of the test methodology. The essential agreement values with the reference method (+/-1 dilution) were >99% for the collection of gram-negative and gram-positive aerobes; >98% for the S. pneumoniae, H. influenzae, and anaerobe collections; and 100% for the group of nonpneumococcal streptococci. These results validate the performance accuracy and utility of Etest tigecycline and verify the reproducibility of this convenient predefined gradient methodology for tigecycline susceptibility determination.

摘要

开展了一项多中心研究,以验证Etest替加环素与临床实验室标准协会参考肉汤微量稀释法和琼脂稀释法相比的效果。对大量革兰氏阴性需氧菌(n = 266)、革兰氏阳性需氧菌(n = 162)、厌氧菌(n = 385)以及非肺炎链球菌(n = 369)、肺炎链球菌(n = 372)和流感嗜血杆菌(n = 372)的选定菌株进行了检测。所有检测方法均使用了对替加环素敏感性降低的菌株。无论采用何种检测方法,Etest对所有受试生物体组均显示出出色的实验室间和实验室内重复性。革兰氏阴性和革兰氏阳性需氧菌集合与参考方法(±1个稀释度)的基本一致率>99%;肺炎链球菌、流感嗜血杆菌和厌氧菌集合的基本一致率>98%;非肺炎链球菌组的基本一致率为100%。这些结果验证了Etest替加环素的性能准确性和实用性,并证实了这种方便的预定义梯度方法用于替加环素敏感性测定的可重复性。